Aprea Therapeutics (NASDAQ:APRE) Releases Earnings Results, Beats Expectations By $0.11 EPS

Aprea Therapeutics (NASDAQ:APRE) announced its quarterly earnings results on Wednesday. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.11, FiscalAI reports. Aprea Therapeutics had a negative net margin of 4,405.59% and a negative return on equity of 61.03%.

Aprea Therapeutics Price Performance

NASDAQ APRE traded up $0.02 during trading on Wednesday, hitting $0.68. 18,337 shares of the company’s stock traded hands, compared to its average volume of 1,020,058. The stock has a fifty day moving average of $0.71 and a two-hundred day moving average of $0.77. Aprea Therapeutics has a 12-month low of $0.55 and a 12-month high of $1.79. The firm has a market cap of $8.40 million, a P/E ratio of -0.44 and a beta of 1.52.

Analysts Set New Price Targets

Several research firms have issued reports on APRE. Wedbush lowered their target price on shares of Aprea Therapeutics from $7.00 to $6.00 and set an “outperform” rating on the stock in a research note on Thursday, May 14th. Oppenheimer started coverage on shares of Aprea Therapeutics in a report on Thursday, May 7th. They issued an “outperform” rating and a $5.00 price target on the stock. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Aprea Therapeutics in a research report on Friday, July 17th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Aprea Therapeutics has an average rating of “Hold” and a consensus target price of $4.07.

Institutional Investors Weigh In On Aprea Therapeutics

An institutional investor recently bought a new position in Aprea Therapeutics stock. Jane Street Group LLC bought a new position in Aprea Therapeutics, Inc. (NASDAQ:APRE) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 46,621 shares of the company’s stock, valued at approximately $40,000. Jane Street Group LLC owned about 0.67% of Aprea Therapeutics as of its most recent filing with the Securities & Exchange Commission. 34.19% of the stock is currently owned by institutional investors.

Aprea Therapeutics Company Profile

Aprea Therapeutics is a clinical?stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.

Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS.